The laser-assisted intradermal delivery of a tumor-specific tumor antigen combined with XCL1 resulted in the enhanced priming of CD8+ and CD4+ effector T cells by dermal DCs and better tumor control in a melanoma mouse model [51]. This evidence concerns the gene XCL1 and melanoma.